PARP1 and neoplasm: (161) also indicated that the combination of PARP inhibitor ABT-888 and radiotherapy prolonged the tumor growth phase in a mouse prostate in situ transplantation tumor model, whereas ABT-888 or radiotherapy alone was less effective.